Published in Clin Pharmacol Ther on December 21, 2011
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years. AIDS (2015) 1.55
Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One (2012) 1.05
Formulations for children: problems and solutions. Br J Clin Pharmacol (2015) 0.87
Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. Br J Clin Pharmacol (2014) 0.82
A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children. Br J Clin Pharmacol (2014) 0.78
Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children. Antimicrob Agents Chemother (2013) 0.77
Dose evaluation of lamivudine in HIV-infected children aged 5 months-18 years based on a population pharmacokinetic analysis. Br J Clin Pharmacol (2017) 0.75
Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children. Pediatr Infect Dis J (2014) 0.75
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med (2010) 6.38
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet (2004) 4.25
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med (2001) 3.74
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS (1998) 3.16
Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. BMJ (1999) 2.68
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother (2004) 2.11
PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med (2004) 2.10
Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS (2001) 1.94
Community intervention to lower blood cholesterol: the "Know Your Cholesterol" campaign in Pawtucket, Rhode Island. Health Educ Q (1986) 1.85
Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis (2012) 1.79
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit (2003) 1.71
Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol (2008) 1.63
Predicting antimicrobial susceptibilities for Escherichia coli and Klebsiella pneumoniae isolates using whole genomic sequence data. J Antimicrob Chemother (2013) 1.61
Descriptive survey of antenatal HIV testing in London: policy, uptake, and detection. BMJ (1996) 1.55
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years. AIDS (2015) 1.55
Prolonged pregnancy: is induction of labour indicated? A prospective study. Br J Obstet Gynaecol (1982) 1.54
Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. Clin Infect Dis (2010) 1.52
Reading disabilities and the effects of colored filters. J Learn Disabil (1990) 1.50
Prediction of Staphylococcus aureus antimicrobial resistance by whole-genome sequencing. J Clin Microbiol (2014) 1.48
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS (1999) 1.42
A comparison between computerised (mean range) and clinical visual cardiotocographic assessment. Br J Obstet Gynaecol (1992) 1.42
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS (2007) 1.40
Uterine activity during spontaneous labour after previous lower-segment caesarean section. Br J Obstet Gynaecol (1989) 1.38
Hospital exposure in a UK population, and its association with bacteraemia. J Hosp Infect (2007) 1.38
Selective antegrade cerebral perfusion attenuates brain metabolic deficit in aortic arch surgery: a prospective randomized trial. Circulation (2004) 1.33
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis (2007) 1.30
Vertically transmitted HIV infection in the British Isles. BMJ (1993) 1.29
Antiretroviral drugs and the central nervous system. AIDS (1998) 1.28
Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet (2000) 1.28
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS (2000) 1.26
Evaluation of two community-wide smoking cessation contests. Prev Med (1987) 1.24
Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother (2005) 1.24
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther (2008) 1.23
Illness understanding in children and adolescents with heart disease. Heart (2000) 1.22
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med (2009) 1.20
Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides. J Med Chem (1996) 1.19
Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. PLoS Med (2013) 1.19
Intermodal perception of expressive behaviors by human infants. J Exp Child Psychol (1982) 1.18
HIV infection in children: epidemiological and diagnostic aspects. Int J STD AIDS (1992) 1.15
Cervical length at 23 weeks of gestation: the value of Shirodkar suture for the short cervix. Ultrasound Obstet Gynecol (1998) 1.14
Age as a determinant of survival in HIV infection. J Clin Epidemiol (2001) 1.14
Carbamazepine--indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother (2000) 1.13
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother (2007) 1.13
Should we abandon Kielland's forceps? Br Med J (Clin Res Ed) (1983) 1.12
Extensive polymorphism in Cryptosporidium parvum identified by multilocus microsatellite analysis. Appl Environ Microbiol (2000) 1.11
Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther (2007) 1.10
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci (1997) 1.10
Mother-to-child transmission of HIV-1 and infant feeding practice. AIDS (2001) 1.10
Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (2000) 1.08
Development of knowledge of visual-tactual affordances of substance. Child Dev (1984) 1.08
Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1999) 1.07
Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection. AIDS (2001) 1.06
High-performance liquid chromatography of HIV protease inhibitors in human biological matrices. J Chromatogr B Biomed Sci Appl (2001) 1.06
Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One (2012) 1.05
Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J (2011) 1.05
Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer (2013) 1.03
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS (1999) 1.02
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS (2010) 1.02
Obstetric characteristics in different racial groups. Br J Obstet Gynaecol (1983) 1.02
Cost effectiveness analysis of antenatal HIV screening in United Kingdom. BMJ (1999) 1.02
Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. J Acquir Immune Defic Syndr (2011) 1.01
Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy. Int J Tuberc Lung Dis (2011) 1.01
Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. Int J Tuberc Lung Dis (2011) 1.01
Comparison of multilocus variable-number tandem-repeat analysis and whole-genome sequencing for investigation of Clostridium difficile transmission. J Clin Microbiol (2013) 1.01
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther (2008) 1.01
Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob Agents Chemother (1995) 1.00
Poor sensitivity and consistency of microscopy in the diagnosis of low grade non-gonococcal urethritis. Sex Transm Infect (2003) 1.00
Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.98
Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol (2008) 0.96
PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med (2002) 0.95
Multiple-strain colonization in nasal carriers of Staphylococcus aureus. J Clin Microbiol (2014) 0.94
Drug interactions with zidovudine. AIDS (1993) 0.94
Selective looking by infants. Cogn Psychol (1981) 0.93
Validity of indirect comparisons in meta-analysis. Lancet (2007) 0.93
Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection. Arch Dis Child (1997) 0.91
The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. Trop Med Int Health (2012) 0.91
Selective versus universal antenatal HIV testing: epidemiological and implementational factors in policy choice. AIDS (1999) 0.91
Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.91
Germline transformation of the diamondback moth, Plutella xylostella L., using the piggyBac transposable element. Insect Mol Biol (2012) 0.90
Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr (2000) 0.89
Predictive value of cervimetric labour patterns in primigravidae. Br J Obstet Gynaecol (1982) 0.89
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. Br J Cancer (2010) 0.88
The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med (2008) 0.88
Conditions for the chemical and physical inactivation of the K. Fu. strain of the agent of Creutzfeldt-Jakob disease. Am J Public Health (1983) 0.88